EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging uncertainty on the anti-aging potential of metformin

Matthew Thomas Keys, Jesper Hallas, Richard A Miller, Samy Suissa, Kaare Christensen

Ageing Research Reviews · 2025-09 · 111 · 102817

DOI: 10.1016/j.arr.2025.102817 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2025-09. Verfasst von Matthew Thomas Keys und 4 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology, Biostatistics, and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark. Electronic address: mke…. Hauptthemen laut MEDLINE: Metformin, Hypoglycemic Agents, Aging. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Velux Stiftung, Velux Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin is the most commonly prescribed glucose-lowering agent worldwide for the treatment of type II diabetes. Due to evidence of improvements in healthspan and lifespan in model organisms, and mechanistic data relevant to the hallmarks of aging, it has been considered a promising candidate in the search for pharmacological interventions that may attenuate the ageing process in humans. Various epidemiological studies have been influential in generating support for this hypothesis. These include pronounced anticancer and cardioprotective benefits compared to other antidiabetic treatments, and an observation of metformin use in type II diabetes being associated with better survival than that of the general population. Here we discuss recent developments in the evidence underlying the rationale for using metformin to target ageing. We describe the methodological limitations of some of the early and most influential findings and critically assess their scientific follow-up, including replication attempts of key experimental and observational findings, and a range of clinical trials of metformin in individuals without type II diabetes. These developments generally illustrate an emerging uncertainty in the anti-aging potential of metformin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminHypoglycemic AgentsAgingHumansDiabetes Mellitus, Type 2AnimalsUncertainty

Stichwörter der Autor:innen

Anti-agingGeroscienceLifespanLongevityMetforminType 2 diabetes

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Epidemiology, Biostatistics, and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark. Electronic address: mkeys@health.sdu.dk.
  • Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
  • Departments of Epidemiology and Biostatistics, and Medicine, McGill University, Montreal, Canada.
  • Epidemiology, Biostatistics, and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark; Danish Ageing Research Centre, University of Southern Denmark, Odense, Denmark.

Förderung

  • NIA NIH HHS
  • Velux Stiftung
  • Velux Foundation

Zitieren

APA

Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025). Emerging uncertainty on the anti-aging potential of metformin. Ageing Research Reviews, 111, 102817. https://doi.org/10.1016/j.arr.2025.102817

Vancouver

Keys MT, Hallas J, Miller RA, Suissa S, Christensen K. Emerging uncertainty on the anti-aging potential of metformin. Ageing Research Reviews. 2025;111:102817. doi:10.1016/j.arr.2025.102817

BibTeX
@article{Keys2025,
  author = {Keys, Matthew Thomas and Hallas, Jesper and Miller, Richard A and Suissa, Samy and Christensen, Kaare},
  title = {Emerging uncertainty on the anti-aging potential of metformin},
  journal = {Ageing Research Reviews},
  year = {2025},
  volume = {111},
  pages = {102817},
  doi = {10.1016/j.arr.2025.102817}
}
Kostenlos starten →